Group 1 - The stock price of Zhenghai Biological as of August 26, 2025, closed at 22.23 yuan, down 0.22 yuan or 0.98% from the previous trading day [1] - The trading volume on that day was 33,418 hands, with a transaction amount of 0.75 billion yuan and a turnover rate of 1.86% [1] - Zhenghai Biological operates in the medical device sector, focusing on the research, production, and sales of biological regenerative materials, including oral repair membranes and biological membranes [1] Group 2 - The company announced that its calcium silicate bioceramic bone repair material is a non-animal-derived synthetic bone repair material, which will be subject to a 13% value-added tax upon market launch [1] - Zhenghai Biological clarified that there are currently no plans to develop non-animal-derived meningeal series products [1] - A temporary shareholders' meeting is scheduled for August 27 to review multiple proposals, including changes to the business scope and amendments to the company’s articles of association [1] Group 3 - On August 26, the net outflow of main funds was 2.4205 million yuan, with a cumulative net outflow of 21.9957 million yuan over the past five days [1]

Core Viewpoint - The company announced that its calcium silicate bio-ceramic bone repair materials are non-animal sourced synthetic bone repair materials, which will be subject to a 13% value-added tax upon future sales [1] Group 1 - The company currently has no plans to develop non-animal sourced meninges series products [1]

Core Viewpoint - Zhenghai Biological (300653.SZ) announced that its calcium silicate bioceramic bone repair materials are non-animal sourced synthetic bone repair materials, which will be subject to a 13% value-added tax upon future sales [1] Group 1 - The company currently has no plans to develop non-animal sourced meninges series products [1]

Meeting Announcement - The company will hold its first extraordinary general meeting of shareholders in 2025 on August 27, 2025, at 14:30 [1] - The meeting will utilize both on-site and online voting methods, with online voting available from 9:15 to 15:00 on the same day [1][2] Shareholder Rights - All shareholders registered by the close of business on August 22, 2025, are entitled to attend the meeting and may appoint proxies to vote on their behalf [2][3] - The meeting will include directors, supervisors, and senior management, as well as a witnessing lawyer [2] Voting Proposals - Certain proposals require a special resolution, needing approval from over two-thirds of the voting rights held by attending shareholders [2] - The proposals have been previously approved in the eighth meeting of the fourth board of directors and the seventh meeting of the fourth supervisory board [2] Registration Process - Corporate shareholders must provide identification and proof of their representative status, while individual shareholders must present their stock account card and identification [3][4] - Remote shareholders can register via mail or fax, with a deadline of August 25, 2025, at 17:00 [4] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system and internet voting system, with detailed procedures provided in the attachments [6] - The voting process includes options for approval, disapproval, or abstention, with specific rules for handling multiple votes on the same proposal [6] Contact Information - For inquiries, shareholders can contact the company’s board office at the provided phone and fax numbers [5]

证券代码：300653 证券简称：正海生物 公告编号：2025-036 股东会提示性公告 烟台正海生物科技股份有限公司 关于召开 2025 年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 经烟台正海生物科技股份有限公司（以下简称"公司"）第四届董事会第八 次会议审议通过，决定于 2025 年 8 月 27 日（星期三）召开 2025 年第一次临时 股东会。公司已于 2025 年 8 月 5 日在巨潮资讯网（www.cninfo.com.cn）上披露 了《关于召开 2025 年第一次临时股东会的通知》（公告编号 2025-035），本次股 东会采用现场投票和网络投票相结合的方式召开，现将本次股东会的有关事宜再 次提示如下： 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、股东会的召集人：公司董事会 3、会议召开的合法、合规性：公司第四届董事会第八次会议审议通过，决 定召开 2025 年第一次临时股东会，召集程序符合有关法律、行政法规、部门规 章、规范性文件和公司章程的规定。 4、会议召开的日期、时间： （ ...

Company Overview - Zhenghai Biological Technology Co., Ltd. is located in Yantai Economic and Technological Development Zone, Shandong Province, established on October 22, 2003, and listed on May 16, 2017. The company specializes in the research, production, and sales of biological regenerative materials [1] - The main business revenue composition includes: 50.99% from meninges series products, 48.98% from oral repair membranes, and 0.03% from other supplementary products [1] Financial Performance - As of June 30, 2025, Zhenghai Biological reported operating revenue of 188 million yuan, a year-on-year decrease of 5.14%, and a net profit attributable to shareholders of 46.49 million yuan, a year-on-year decrease of 45.97% [2] - The company has cumulatively distributed 617 million yuan in dividends since its A-share listing, with 334 million yuan distributed over the past three years [3] Stock Performance - On August 25, the stock price of Zhenghai Biological increased by 2.07%, reaching 22.70 yuan per share, with a trading volume of 113 million yuan and a turnover rate of 2.81%, resulting in a total market capitalization of 4.086 billion yuan [1] - Year-to-date, the stock price has risen by 8.89%, with a 1.52% increase over the last five trading days, a 0.89% increase over the last twenty days, and a 12.38% increase over the last sixty days [1] Shareholder Information - As of June 30, 2025, the number of shareholders is 16,800, a decrease of 0.89% from the previous period, with an average of 10,704 circulating shares per person, an increase of 0.90% [2] - Among the top ten circulating shareholders, Dongfanghong New Power Mixed A (000480) is the fourth largest with 1.2268 million shares, an increase of 526,800 shares from the previous period. Dongfanghong JD Big Data Mixed A (001564) is the sixth largest, a new shareholder with 656,000 shares [3]

Core Viewpoint - Zhenghai Biological's stock price has shown a slight increase, but the company is facing significant challenges with declining revenue and profits due to reliance on core products and slow progress in new product development [1] Company Overview - Zhenghai Biological specializes in the research, production, and sales of bio-regenerative materials, including oral repair membranes and absorbable dura (spinal) membranes, positioning itself as one of the early entrants in the regenerative medicine field within the Class III implantable medical device sector [1] Financial Performance - For the first half of 2025, the company reported a revenue decline of 5.14% to 187 million yuan, with a net profit attributable to shareholders of 46.49 million yuan, down 45.97% year-on-year [1] - The decline in performance is primarily attributed to a 19.38% drop in revenue from oral repair membranes, a 38.87% increase in sales expenses, and adjustments in tax rates [1] Product Dependency and Development - The company's core products remain heavily dependent on oral repair membranes and dura patches, while new products such as active biological bone have not yet achieved significant sales volume, and the progress of the research pipeline is slow [1] Market Activity - On August 15, 2025, the net outflow of main funds for Zhenghai Biological was 855,500 yuan, while the cumulative net inflow over the past five days was 9.20 million yuan [1]

Core Viewpoint - Zhenghai Biological is at a crossroads of transformation as its marketing expenses surged by 39%, yet it failed to achieve revenue growth, with a significant decline in net profit and core product revenues [4][5] Financial Performance - The company reported a 5.14% year-on-year decline in revenue to 187 million yuan, while net profit dropped by 45.97% to 46.49 million yuan, and non-recurring net profit fell by 46.77% to 40.28 million yuan [4][6] - The main reasons for the profit decline include a nearly 20% drop in oral repair membrane revenue, increased cost pressures, and changes in the external environment [4][6] Product Performance - The sales revenue of the brain membrane series products increased by 5.88% to 80.27 million yuan, becoming a rare highlight in the report, attributed to successful bids in multiple provincial alliances [6] - Conversely, the oral repair membrane business saw a revenue decline of 19.38% to 77.12 million yuan, with a decrease in gross margin by 1.63 percentage points to 85.98% [6][7] - The decline in oral repair membrane revenue is attributed to weak market demand, intensified competition, and continuous price reductions [6][7] Tax and Regulatory Impact - Starting January 1, 2025, the VAT on key raw materials for Zhenghai Biological's main products will increase from a simplified rate of 3% to a general rate of 13%, significantly eroding profit margins [7] Structural Issues - The company's revenue structure is heavily reliant on two main products, which account for over 80% of total revenue, making it vulnerable to market fluctuations [6][7] Marketing and Sales Strategy - In response to declining performance, the company increased its sales expenses to 71.18 million yuan, a 38.87% increase, primarily for market promotion and commercial support [8] - The sales expense ratio rose from 25.88% to 37.90%, while net profit margin decreased from 43.45% to 24.75%, indicating a mismatch between marketing investment and revenue generation [8][9] New Product Development - The company is pinning hopes on new products like active biological bone, which has not yet generated significant sales despite being registered for nearly three years [9][10] - Other in-development products are progressing slowly, with potential revenue contributions expected in 2-3 years, which may not address immediate financial pressures [10] International Expansion - The company is exploring international markets, which present significant potential but require higher standards for product quality, certification, and marketing capabilities [10]

Group 1 - The company, Zhenghai Biological, confirmed that its products, including absorbable dura mater (spinal) patches, are primarily used in neurosurgery for the repair of dura mater (spinal) defects caused by various reasons [2] - The company's dura mater series products are not specifically mentioned to be applicable in brain engineering, but they are designed for medical applications related to the nervous system [2] - The interaction took place on an investor communication platform, indicating active engagement with investors regarding product applications [2]

格隆汇8月14日丨正海生物(300653.SZ)在互动平台表示，公司目前尚未开展人工子宫产品的研发及合 作。 ...